Item

Russian-developed COVID-19 Vaccine Interim Trial Reports 92% Success Rate

Title (Dublin Core)

Russian-developed COVID-19 Vaccine Interim Trial Reports 92% Success Rate

Description (Dublin Core)

Following initial findings of Pfizer's vaccine being effective in preventing COVID-19 infection in more than 90% of people, Russia says its vaccine has 92% efficacy according to preliminary findings in stage three of the clinical trials. The trial results are based on 20 confirmed COVID-19 cases.

Date (Dublin Core)

Creator (Dublin Core)

Contributor (Dublin Core)

Event Identifier (Dublin Core)

Partner (Dublin Core)

Type (Dublin Core)

screenshot

Link (Bibliographic Ontology)

Controlled Vocabulary (Dublin Core)

Curator's Tags (Omeka Classic)

Contributor's Tags (a true folksonomy) (Friend of a Friend)

Collection (Dublin Core)

English

Linked Data (Dublin Core)

Date Submitted (Dublin Core)

11/12/2020

Date Modified (Dublin Core)

11/13/2020
1/31/2021
03/15/2021

Date Created (Dublin Core)

11/11/2020

Item sets

This item was submitted on November 12, 2020 by Tina Chang using the form “Share Your Story” on the site “A Journal of the Plague Year”: http://mail.covid-19archive.org/s/archive

Click here to view the collected data.

New Tags

I recognize that my tagging suggestions may be rejected by site curators. I agree with terms of use and I accept to free my contribution under the licence CC BY-SA